You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華領醫藥(02552.HK)與拜耳就新型糖尿病藥達成合作
阿思達克 08-17 17:17
華領醫藥-B(02552.HK)公布,全資附屬華領醫藥技術,與拜耳醫藥保健有限公司(拜耳)就新型糖尿病治療藥物dorzagliatin在中國達成商業合作協定。

根據協定條款,公司作為藥品上市許可持有人將負責臨床開發,註冊,產品供應以及分銷工作;拜耳作為推廣服務提供方將負責該產品在中國的市場行銷,推廣以及醫學教育活動。華領醫藥將獲得3億元人民幣(下同)的預付款,此外其還將獲得額外最高可達到41.8億元的銷售里程碑付款。

拜耳公司獲得該產品在中國獨家商業化的權利,並將根據華領淨銷售額的一定比例獲得服務費用。雙方在初期將平均分享來自該產品在中國的淨銷售收入,並在未來銷售額達到一定量級時,對銷售收入分配比例進行相應調整。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account